Results 201 to 210 of about 3,628 (221)

Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)

European Heart Journal - Cardiovascular Pharmacotherapy, 2019
Per Grimfjärd, David Erlinge, Christoph Varenhorst   +2 more
exaly  

Randomized Comparison of Oral P2Y12-Receptor Inhibitor Loading Strategies for Transitioning From Cangrelor

JACC: Cardiovascular Interventions, 2017
Dietmar Trenk, Franz-Josef Neumann
exaly  

Aspirin/cangrelor/heparin

Reactions Weekly, 2021
openaire   +1 more source

Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist

Journal of Clinical Pharmacology, 2010
Julie H Oestreich, Steve Steinhubl
exaly  

Cangrelor

2008
openaire   +1 more source

Aspirin/cangrelor/ticagrelor

Reactions Weekly, 2022
openaire   +1 more source

Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12receptorsin vitro

Platelets, 2016
Robert J Buckland, Robert F Storey
exaly  

Cangrelor/ticagrelor interaction

Reactions Weekly, 2022
openaire   +1 more source

Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor–Mediated Signaling in Prasugrel-Treated Patients

JACC: Cardiovascular Interventions, 2014
Fabiana Rollini, Francesco Franchi, Antonio Tello-Montoliu   +2 more
exaly  

Cangrelor/heparin

Reactions Weekly, 2019
openaire   +1 more source